Knight & TherapeuticsMD amid filing a NDS for Joyesta™ in Canada
Category: #health  By Pankaj Singh  Date: 2019-10-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Knight & TherapeuticsMD amid filing a NDS for Joyesta™ in Canada

Knight Therapeutics Inc., a pharmaceutical company based in Canada, had last year entered a licensing agreement with drug manufacturer TherapeuticsMD, Inc. to gain sale rights for TX-004HR and TX-001HR in Israel and Canada. However, the two firms have recently taken their partnership to the next level by announcing plans for filing a NDS (New Drug Submission) for Joyesta™ in Canada.

For the record, Joyesta is an applicator-free estradiol softgel vaginal drug licensed from TherapeuticsMD to treat postmenopausal symptoms of vaginal and vulvar atrophy caused due to estrogen deficiency. The drug is marketed as IMVEXXY® in the U.S. for the treatment of mild to severe dyspareunia.

Speaking on the recent move, Jonathan Ross Goodman, CEO, Knight, said that their firm is looking forward to bringing Joyesta to Canadian patients. He claims that, with more than 50% of postmenopausal women living with its symptoms, their company is thrilled about the potential of Joyesta to address patient’s needs.

According to Robert Finizio, CEO, TherapeuticsMD, they are pleased to partner with Knight’s team as their firm works to bring this essential product to women in Canada.

Reportedly, the licensing agreement signed between the two firms last year included Knight paying TherapeuticsMD a landmark fee upon initial regulatory approval in Canada of each of TX-004HR and TX-001HR.

It also included sales milestone fees based on certain annual sales in Israel and Canada of each of TX-001HR and TX-004HR, as well as royalties. Additionally, Knight was responsible for all commercial and regulatory activities in Israel and Canada related to TX-004HR and TX-001HR.

As for IMVEXXY is concerned, it is the only product in the therapeutic class to provide a 4 mcg & a 10 mcg drug dose, with the 4 mcg demonstrating the lowest U.S. FDA (Food and Drug Administration)-approved drug of vaginal estradiol.
 

Source Credit: https://ir.therapeuticsmd.com/news-releases/news-release-details/knight-and-therapeuticsmd-announce-filing-new-drug-submission



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...